Analyzing Check Cap (CHEK) & Its Competitors
Check Cap (NASDAQ: CHEK) is one of 19 publicly-traded companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Check Cap to similar companies based on the strength of its dividends, institutional ownership, valuation, profitability, risk, analyst recommendations and earnings.
This is a summary of recent recommendations for Check Cap and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Check Cap Competitors||97||365||959||28||2.63|
Check Cap presently has a consensus target price of $6.00, indicating a potential upside of 242.84%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 25.53%. Given Check Cap’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Check Cap is more favorable than its competitors.
Volatility and Risk
Check Cap has a beta of -0.37, meaning that its share price is 137% less volatile than the S&P 500. Comparatively, Check Cap’s competitors have a beta of 0.81, meaning that their average share price is 19% less volatile than the S&P 500.
Insider and Institutional Ownership
19.3% of Check Cap shares are held by institutional investors. Comparatively, 66.5% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by institutional investors. 10.0% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This table compares Check Cap and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Check Cap Competitors||-538.85%||-41.85%||-24.81%|
Earnings and Valuation
This table compares Check Cap and its competitors revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Check Cap||N/A||-$9.62 million||-2.97|
|Check Cap Competitors||$2.57 billion||$977.16 million||3.58|
Check Cap’s competitors have higher revenue and earnings than Check Cap. Check Cap is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Check Cap competitors beat Check Cap on 8 of the 12 factors compared.
About Check Cap
Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing. The Company’s scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. Its scanning capsule employs low-dose X-rays, which allow the system to image the interior lining of the colon even when surrounded by intestinal content. Its capsule transmits information to a receiving device worn on the patient’s body that stores the information for off-line analysis.
Receive News & Ratings for Check Cap Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap Ltd and related companies with MarketBeat.com's FREE daily email newsletter.